Scilex Holding Co (SCLXW) company profile
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
About Scilex
Biological Products, (No Diagnostic Substances), SIC 2836
Scilex focuses on developing and commercializing non-opioid treatments for acute and chronic pain conditions. Its commercial portfolio includes ZTlido, a prescription topical lidocaine delivery system for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an oral solution indicated for the acute treatment of migraine in adults; and GLOPERBA, a liquid oral medication for preventing gout flares. The company also advances investigational candidates targeting sciatica, acute lower back pain, and fibromyalgia. Its treatments serve adult patients suffering from severe pain disorders, distributed through national and regional wholesalers and retail pharmacies following prescriptions from physicians and specialists.
Commercial operations and marketing efforts are centered in the United States, with regulatory filings also extending into Canada. Product manufacturing is conducted internationally, with topical patch production handled by a partner in Japan. Commercial distribution relies on a nationwide network of pharmacies, healthcare providers, and regional wholesalers across the country.
Summary of the business section of Scilex's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Scilex Holding Co
- Founded
- 2013
- Headquarters
- Palo Alto, CA
- Address
- 960 San Antonio Road 94303
- Phone
- (650) 516-4310
- Website
- scilexholding.com
- Employees
- 34, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BPM LLP, Walnut Creek, California
Stock & identifiers
- Ticker
- SCLXW
- Other tickers
- SCLX
- Exchange
- Nasdaq
- IPO date
- Jan 8, 2021
- Shares outstanding
- 8M, Aug 10, 2026
- Public float
- $32.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-35 reverse, Apr 15, 2025; 19-for-4, Aug 12, 2022
- SEC CIK
- 1820190
- CUSIP
- 80880W114
- ISIN
- US80880W1146
- FIGI
- BBG00YM315Z3
- LEI
- 529900SPEA2C7YTTYP45
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen Hoi Ma | CFO, COO and Secretary, Director | 22,840 |
| Henry Ji | Exec Chair, CEO and President, Director | 678,135 |
| Jaisim Shah | See Remarks, Director | 295,215 |
| Jay Chun | Director | 112,511 |
| Dorman Followwill | Director | 2,300 |
| Yue Alexander Wu | Director | 25,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Jaisim Shah Former Chief Executive Officer, President and Director | $1.25M | – | $21.04K | $1.27M | +0% |
| Henry Ji Chief Executive Officer, President and Executive Chairperson | $1.56M | $1.49M | $18.30K | $3.07M | +143% |
| Stephen Ma Chief Financial Officer, Chief Operating Officer, Senior Vice President and Secretary | $696.49K | $746.77K | $22.29K | $1.47M | +139% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Jan 8, 2021
- Securities offered
- 12,000,000
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Jul 7, 2021
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 34 full-time employees, including three employees who have M.D.s or Ph.D.s.”
Corporate history
Events identified from SEC filings